Polipathy among the elderly

About the authors:

Oksana M. Rudakova, post-graduate student, Department of Internal Medicine,
Outpatient Therapy and Family Medicine, Tyumen State Medical Academy
Tatiana V. Bolotnova , Dr. Med. Sci., Head of the Department of Internal Medicine,
Outpatient Therapy and Family Medicine, Tyumen State Medical Academy

Abstract:

An elderly person is considered to be a person over 65 years old. Currently, this category comprises about 15% of the population both in Russia and in many industrialized countries. The prevalence of hypertension in this age group is 50%. Turning to the figures of morbidity rate among the people of different age groups, provided by the National Center for Health, we can clearly see that percentage of cardiovascular disease increases significantly with ageing. The prevalence of cardiovascular disease increases due to the aging population, changed lifestyles, and lack of current prevention programs. Elderly patients are characterized by a number of features including widespread comorbidity (coronary heart disease, diabetes, chronic lung disease, heart failure, renal dysfunction, peripheral atherosclerosis, neurological and orthopedic pathology, etc.). Reduction in cardiovascular morbidity and mortality in recent years has become one of the main tasks of practical medicine. Early diagnosis of such important risk factors as hypertension, dyslipidemia, abdominal obesity and carbohydrate metabolism are the major ways of dealing with it.

References:

1. Organov, R.G., Maslennikova, G.Ja. Cardiovascular Diseases in RF in the Second Half

of XX Century: Tendencies, Possible Causes and Perspectives. Kardiologija — Cariology.

2000; 40: 6: 4-8 (in Russian).

2. Pozdnjakov, Ju.M., Marcevich, S.Ju., Koltunov, I.E., Urinskij, A.M. Stable Breast Pang.

Kardiologija: nacional'noe rukovodstvo — Cardiology: National Manual / ed. by

Belenkova Yu.N., Organova R.G. Moscow, 2007. 636 p. (in Russian).

3. Minushkina, L.О., Voronko, О.Е., Brazhnik, V.А. et. al. Genetic Risk Factors of Left

Ventricular Hypertrophy and Diastolic Dysfunction among Patients with Arterial Hyperrtension [Geneticheskie faktory riska razvitija gipertrofii levogo zheludochka i diastolicheskoj disfunkcii u pacientov s arterial'noj gipertoniej]. Materialy nacional'nogo Kongressa kardiologov «Perspektivy rossijskoj kardiologii» (Materials of the National Cardiologists’ Congress “Perspectives of Russian Cardiology”). Moscow, 2005. 216 p. (in Russian).

4. Nebieridze, D.V. ACE Inhibitors: Metabolic and Vascular Effects. RMZh — RMJ.

2005. Vol. 13. № 15. Pp 3-6 (in Russian).

5. Yusuf, S., Hawken, S., Ounpuu, S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTER-HEART study); case-control study. Lancet. 2004; 364: 937-52.

6. American Diabetes Association. Diabetes and classification of diabetes mellitus. Diabetes care. 2004, 27 (suppl. 1), S5-S10.

7. Zimmet, P. “Prediabetes” — a global snapshot. 1st. Int. Congress on “Prediabetes” and

The Metabolic Syndrome. Berlin, 2006, Abstr. 1.

8. Qiao, Q., Lindstrom, J., Valle, T., Tuomilehto, J. Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycaemia. Diabet

Med. 2003 Dec; 20 (12): 1027-33.

9. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. European Heart

Journal Supplements. 2007; 9 (Suppl. C) ISSN 1520-765.

10. Kannel, W.B. Risk stratification in hypertension: new insights from the Framingham

Study. Am J Hypertens. 2000; 13 (1 Pt 2):3S-10S.

11. Shal'nova, S.A., Deev, A.D., Organov, R.G. Prevalence of the main Risk Factors

among Men and Women over 30 years old in the Russian Federation. Kardiovaskuljarnaja terapija i profilaktika — Cardiovascular Therapy and Prevention. 2005; 1:4-9.

12. Fourth Joint Task Forse of the European Society of Cardiology and Other Societies

on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invinted experts), Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J. 2007; 28: 2375-414.

13. Maet, С. et al. The role of non-esterified fatty acids in the deterioration of glucose

tolerance in Caucasian subjects: results of the Paris rospective Study.Diabetologia. 1997;

40 (9): Pp. 1101-1106.

14. Byrne, C.D., Wareham, N.J., Brown, D.C., Clark, P.M., Cox, L.J., Day, N.E., Palmer,

C.R., Wang, T.W., Williams, D.R., Hales, C.N. Hypertriglyceridaemia in subjects with normal and abnormal glucose tolerance: relative contributions of insulin secretion, insulin resistance and suppression of plasma non-esterified fatty acids. Diabetologia. 1994; 37: Pp. 889–896.

15. Pilz, S. et al. Elevated plasma free fatty acids predict sudden cardiac death: a 6.85 - year follow-up of 3315 patients after coronary angiography. Eur. Heart J. 2007; 28(22):

Pp 763-2769.